- Current report filing (8-K)
July 20 2010 - 12:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 13, 2010
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
Commission File Number 1-9601
|
|
|
|
|
Delaware
|
|
1-9601
|
|
43-0618919
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
One Corporate Woods Drive Bridgeton, MO
|
|
63044
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(314)
645-6600
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item 7.01
|
Regulation FD Disclosure.
|
On July 13, 2010, K-V Pharmaceutical Company (the Registrant) announced in a press release that it has been informed by
Hologic, Inc. that a resubmission to the FDAs Complete Response action letter received in January 2009 has been submitted to the FDA for Gestiva (hydroxyprogesterone caproate injection) 250 mg/mL.
A copy of the press release is attached hereto as Exhibit 99. The information in this Item 7.01, including the exhibit, shall not be
deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.
The Registrant will post this Form 8-K on its Internet website at www.kvpharmaceutical.com. References to the Registrants website
address are included in this Form 8-K and the press release only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the Registrants website does not constitute
part of this Form 8-K or the press release.
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
The following exhibit is furnished as part of this report:
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99
|
|
Press Release dated July 13, 2010, issued by K-V Pharmaceutical Company.
|
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dated: July 20, 2010
|
|
|
K-V PHARMACEUTICAL COMPANY
|
|
|
By:
|
|
/s/ G
REGORY
J. D
IVIS
,
J
R
.
|
|
|
Gregory J. Divis, Jr.
|
|
|
Interim President and Interim Chief Executive Officer
|
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From May 2024 to Jun 2024
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From Jun 2023 to Jun 2024